What is the 13F Pro Quality Score for GYRE?

13F Pro ranks GYRE THERAPEUTICS, INC. (GYRE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View GYRE's current score at https://13fpro.ai/company/GYRE (free sign-up required for the full ranking).

Which hedge funds own the most GYRE stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of GYRE include SC CHINA HOLDING Ltd, BlackRock,, Octagon Capital Advisors. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/GYRE as soon as new 13F filings post.

Where does 13F Pro source GYRE data?

All GYRE THERAPEUTICS, INC. fundamentals and ownership data come directly from SEC EDGAR. GYRE THERAPEUTICS, INC. files with the SEC under CIK 1124105. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is GYRE in?

GYRE THERAPEUTICS, INC. (GYRE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is GYRE research updated on 13F Pro?

GYRE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

GYRE THERAPEUTICS, INC.(GYRE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1124105 GYRE stock profile & AI dashboard →

13F Pro Quality Score

24.4/100

Rank #2,697 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

27.9/100

Profitability

14.2/100

Balance Sheet

13.6/100

Earnings Quality

42.7/100

Free Cash Flow

20.1/100

Institutional Flow

72.8/100

Revenue Scale

17.7/100

Dilution Risk

22.0/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why GYRE Scores 24/100

exact factor attribution · 2026-09-11

GYRE's composite is driven by institutional flow, held back by profitability and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

+1.1 pts

73th pct

Earnings quality

-0.7 pts

43th pct

Shareholder dilution

-1.4 pts

22th pct

Earnings growth

-1.8 pts

14th pct

Capital efficiency

-3.6 pts

14th pct

Revenue growth

-4.4 pts

28th pct

Free cash flow

-4.5 pts

20th pct

Scale

-4.8 pts

18th pct

Profitability

-5.4 pts

14th pct

Latest change (2026-08-07): 29 → 40 · ↑ Capital efficiency 30→70; ↑ Profit margin 25→50; despite ↓ Earnings growth 30→8

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in GYRE

Events flagged as statistical outliers against GYRE's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-07
GYRE quality score jumped 10 points (29→40) on a new filing
View source filing →

GYRE Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for GYRE THERAPEUTICS, INC. (GYRE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GYRE at 24.4/100 on a 32-signal composite quality model, placing it at rank #2,697 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (13.6) and profitability (14.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 22.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), GYRE THERAPEUTICS, INC. reports quarterly revenue of $29.1M, net income of $-14.3M, free cash flow of $-17.0M. Top institutional holders of GYRE by reported 13-F value include SC CHINA HOLDING Ltd, BlackRock, Octagon Capital Advisors, based on the most recent SEC filings. GYRE trades on the Nasdaq exchange and files with the SEC under CIK 1124105. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GYRE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GYRE THERAPEUTICS, INC. directly from SEC EDGAR. GYRE THERAPEUTICS, INC.'s 13F Pro composite quality score has ranged between 24 and 71 since 2024, currently 24.4 — a declining long-term trajectory across 57 quarterly and live scoring snapshots.

✦

Fun facts about GYRE THERAPEUTICS, INC.

Quirks, history, and lore behind GYRE — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap biopharmaceutical company · listed on Nasdaq · focused on developing therapies for fibrotic and inflammatory diseases.
2
The Numbers
Revenue in the range of tens of millions of dollars annually, with operations spanning both U.S. and China — a dual-market footprint unusual for a company this size.
3
The History
The company underwent a significant rebranding and strategic pivot in the early 2020s, shifting its identity toward fibrosis-focused drug development after earlier incarnations under a different name.
4
The Secret
Its lead pipeline leans heavily on compounds targeting TGF-β pathways — a biological mechanism tied to scarring and tissue damage that affects millions with liver and lung fibrosis.
5
The Lore
The company's name evokes a spiral or circular motion — apt for a biotech that keeps cycling back to the same stubborn disease biology that the rest of pharma hasn't cracked.
6
The Giveaway
Its ticker spells out a spinning ocean current, and its mission is to untangle the fibrotic web in diseases like NASH and IPF — this is Gyre Therapeutics.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$29.1M

Net Income

Q2 2026

$-14.3M

Free Cash Flow

Q2 2026

$-17.0M

ROIC

Q2 2026

-53.2%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+10.2% YoY

$116.6MFY 2025

FY22 $102.3MFY23 $113.5MFY24 $105.8MFY25 $116.6M

Net Income

-44.8% YoY

$9.9MFY 2025

FY22 $4.3MFY23 $-85.5MFY24 $17.9MFY25 $9.9M

Operating Income

-28.9% YoY

$11.5MFY 2025

FY22 $9.2MFY23 $-67.2MFY24 $16.2MFY25 $11.5M

EPS (Diluted)

-60.0% YoY

$0.02FY 2025

FY22 $0.03FY23 $-1.41FY24 $0.05FY25 $0.02

Total Assets

+75.2% YoY

$219.8MFY 2025

FY22 $28.4MFY23 $116.5MFY24 $125.4MFY25 $219.8M

Op. Cash Flow

+127.7% YoY

$1.0MFY 2025

FY22 $10.7MFY23 $25.9MFY24 $-3.6MFY25 $1.0M

Free Cash Flow

+97.0% YoY

$-180.0KFY 2025

FY22 $5.7MFY23 $17.4MFY24 $-6.0MFY25 $-180.0K

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$116.6M +10.2%	$105.8M -6.8%	$113.5M +10.9%	$102.3M +1294.0%	$7.3M -65.0%	$20.9M
Net Income	$9.9M -44.8%	$17.9M +120.9%	$-85.5M -2081.5%	$4.3M +104.9%	$-87.9M -56.4%	$-56.2M
Operating Income	$11.5M -28.9%	$16.2M +124.0%	$-67.2M -830.5%	$9.2M +110.5%	$-87.9M -53.2%	$-57.4M
EPS (Diluted)	$0.02 -60.0%	$0.05 +103.5%	$-1.41 -4800.0%	$0.03 +102.1%	$-1.44	—
Total Assets	$219.8M +75.2%	$125.4M +7.6%	$116.5M +309.7%	$28.4M -48.9%	$55.7M -41.3%	$94.8M
Operating Cash Flow	$1.0M +127.7%	$-3.6M -114.1%	$25.9M +142.5%	$10.7M +112.7%	$-83.8M -52.1%	$-55.0M
Free Cash Flow	$-180.0K +97.0%	$-6.0M -134.3%	$17.4M +205.3%	$5.7M +106.7%	$-84.6M	—

Get alerted when GYRE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for GYRE THERAPEUTICS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of GYRE

SC CHINA HOLDING Ltd
$24.7M3,750,299 sh
BlackRock, Inc.
$6.6M993,943 sh
Octagon Capital Advisors LP
$6.3M954,416 sh
VANGUARD CAPITAL MANAGEMENT LLC
$5.8M876,927 sh
GEODE CAPITAL MANAGEMENT, LLC
$3.5M532,950 sh
STATE STREET CORP
$1.6M245,402 sh
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$1.2M184,286 sh
NORTHERN TRUST CORP
$1.1M169,537 sh
SBI Securities Co., Ltd.
$1.1M166,750 sh
VANGUARD FIDUCIARY TRUST CO
$995.6K151,073 sh

Fund	Value	Shares
SC CHINA HOLDING Ltd	$24.7M	3,750,299
BlackRock, Inc.	$6.6M	993,943
Octagon Capital Advisors LP	$6.3M	954,416
VANGUARD CAPITAL MANAGEMENT LLC	$5.8M	876,927
GEODE CAPITAL MANAGEMENT, LLC	$3.5M	532,950
STATE STREET CORP	$1.6M	245,402
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	$1.2M	184,286
NORTHERN TRUST CORP	$1.1M	169,537
SBI Securities Co., Ltd.	$1.1M	166,750
VANGUARD FIDUCIARY TRUST CO	$995.6K	151,073

Companies Similar to GYRE

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

BNR

Burning Rock Biotech Ltd

AI score

Very similar · 1 shared holders

SC CHINA HOLDING Ltd

THCH

TH International Ltd

AI score

Shared smart-money ownership · 1 shared holders

SC CHINA HOLDING Ltd

DTIL

PRECISION BIOSCIENCES INC

AI score